Ritchie Bros (RBA) Shareholder Mondrian Investment Partners LTD Has Lifted Its Holding by $38.78 Million; Abbvie (ABBV) Holder Steinberg Global Asset Management Has Decreased Position by $1.42 Million

February 21, 2018 - By Dolores Ford

Steinberg Global Asset Management decreased its stake in Abbvie Inc (ABBV) by 16.35% based on its latest 2017Q3 regulatory filing with the SEC. Steinberg Global Asset Management sold 16,121 shares as the company’s stock rose 6.17% with the market. The institutional investor held 82,450 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $7.33 million, down from 98,571 at the end of the previous reported quarter. Steinberg Global Asset Management who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $187.35 billion market cap company. The stock decreased 0.52% or $0.62 during the last trading session, reaching $117.98. About 8.75M shares traded or 45.70% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 21, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Mondrian Investment Partners Ltd increased its stake in Ritchie Bros (RBA) by 35.9% based on its latest 2017Q3 regulatory filing with the SEC. Mondrian Investment Partners Ltd bought 994,240 shares as the company’s stock rose 0.87% with the market. The institutional investor held 3.76M shares of the business services company at the end of 2017Q3, valued at $148.48 million, up from 2.77M at the end of the previous reported quarter. Mondrian Investment Partners Ltd who had been investing in Ritchie Bros for a number of months, seems to be bullish on the $3.44 billion market cap company. The stock decreased 0.96% or $0.31 during the last trading session, reaching $32.05. About 674,786 shares traded or 7.93% up from the average. Ritchie Bros. Auctioneers Incorporated (NYSE:RBA) has declined 2.22% since February 21, 2017 and is downtrending. It has underperformed by 18.92% the S&P500.

Since September 11, 2017, it had 0 insider purchases, and 5 selling transactions for $25.59 million activity. The insider RICHMOND TIMOTHY J. sold $8.57M. Gosebruch Henry O sold $1.66M worth of AbbVie Inc. (NYSE:ABBV) on Monday, October 30. Shares for $705,655 were sold by SALEKI-GERHARDT AZITA on Monday, September 11. Another trade for 6,699 shares valued at $589,512 was sold by Michael Robert A..

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on April, 26. They expect $1.78 earnings per share, up 39.06% or $0.50 from last year’s $1.28 per share. ABBV’s profit will be $2.83 billion for 16.57 P/E if the $1.78 EPS becomes a reality. After $1.48 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 20.27% EPS growth.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Friday, September 15 by Jefferies. The company was maintained on Friday, February 2 by Argus Research. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Thursday, May 25 by Jefferies. The company was upgraded on Monday, October 2 by Leerink Swann. On Thursday, September 28 the stock rating was maintained by Piper Jaffray with “Buy”. The stock has “Hold” rating by Credit Suisse on Wednesday, June 7. BMO Capital Markets maintained AbbVie Inc. (NYSE:ABBV) on Friday, April 28 with “Hold” rating. The stock of AbbVie Inc. (NYSE:ABBV) earned “Outperform” rating by William Blair on Friday, February 5. BMO Capital Markets maintained the stock with “Hold” rating in Wednesday, June 7 report. The rating was downgraded by UBS on Monday, September 25 to “Neutral”.

Steinberg Global Asset Management, which manages about $604.10 million and $680.23M US Long portfolio, upped its stake in Schein Henry Inc (NASDAQ:HSIC) by 9,706 shares to 19,412 shares, valued at $1.59M in 2017Q3, according to the filing. It also increased its holding in Ishares Tr (IEFA) by 4,776 shares in the quarter, for a total of 49,192 shares, and has risen its stake in Ncr Corp New (NYSE:NCR).

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.15, from 1 in 2017Q2. It dived, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. 42,347 are owned by Eagle Management Ltd Liability Company. Mckinley Carter Wealth Services reported 6,849 shares. Sand Hill Global Advsr Ltd Co accumulated 3,100 shares. Advisor Prns Ltd Com accumulated 0.61% or 34,878 shares. Gradient Invs Llc invested in 0.59% or 103,962 shares. Blue Chip Prtnrs stated it has 2.71% in AbbVie Inc. (NYSE:ABBV). Louisiana State Employees Retirement Sys owns 99,500 shares. Schulhoff & Inc reported 23,912 shares. Sns Financial Group Inc Ltd Com holds 1.48% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 65,042 shares. Monroe Bancorp Trust Mi invested 0.03% of its portfolio in AbbVie Inc. (NYSE:ABBV). Anchor Cap Advsr Ltd Llc reported 9,025 shares or 0.03% of all its holdings. Schwartz Inv Counsel holds 2,400 shares or 0.01% of its portfolio. Meiji Yasuda Life Co holds 53,316 shares or 0.7% of its portfolio. Renaissance Technologies Limited Liability Co has invested 0.15% of its portfolio in AbbVie Inc. (NYSE:ABBV). One National Association invested in 0.92% or 148,339 shares.

Mondrian Investment Partners Ltd, which manages about $70.36 billion and $3.94 billion US Long portfolio, decreased its stake in At & T Inc (NYSE:T) by 16,537 shares to 846,855 shares, valued at $33.17M in 2017Q3, according to the filing. It also reduced its holding in Actuant (NYSE:ATU) by 715,999 shares in the quarter, leaving it with 684,640 shares, and cut its stake in Omnicell (NASDAQ:OMCL).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts